Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (11987)	12/2/1997 4:25:00 PM
From: Alper H.YUKSEL	Read Replies (1) \| Respond to of 32384

> Viracept was a huge success, but I've always wondered if it was due to "rationale drug design" or luck. < With all due respect, I'd rather be lucky than smart :) Alper

To: Henry Niman who wrote (11987)	12/2/1997 4:29:00 PM
From: Andrew H	Respond to of 32384

I'll check out what they are saying on the AGPH thread. There's got to be a certain degree of luck in all successful products. One really doesn't know without human trials. As for having a lot of cash, maybe they can buy some smaller biotechs with good pipelines. Its definately true what you say about LGND's pipeline and that bodes well for the future, but its hard to tell how far in the future. The RS projection of $14.55 is really based on a lot of guesses. Time will tell. Meanwhile, it would be nice to hear about the final Panretin KS trial, the selection of the LLY drug and the 3 news articles. Results from the P2 could be a big help to the stock price as well, but we may not get those. In any case, its probably wise to be looking for a couple of bottles of wine. (:>)